Expansion of a subset of CD14(high)CD16(neg)CCR2(low/neg) monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection

Imagem de Miniatura
Arquivos
art_GAMA_Expansion_of_a_subset_of_CD14(high)CD16(neg)CCR2(low_neg)_monocytes_2012_eng.pdf (2.84 MB)
Citações na Scopus
52
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FEDERATION AMER SOC EXP BIOL
Autores
SHIRK, Erin N.
RUSSELL, Julia N.
LI, Ming
QUEEN, Suzanne E.
ZINK, M. Christine
CLEMENTS, Janice E.
Citação
JOURNAL OF LEUKOCYTE BIOLOGY, v.91, n.5, p.803-816, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Monocytes have been categorized in three main subpopulations based on CD14 and CD16 surface expression. Classical monocytes express the CD14(++)CD16(-) CCR2(+) phenotype and migrate to inflammatory sites by quickly responding to CCL2 signaling. Here, we identified and characterized the expansion of a novel monocyte subset during HIV and SIV infection, which were undistinguishable from classical monocytes, based on CD14 and CD16 expression, but expressed significantly lower surface CCR2. Transcriptome analysis of sorted cells demonstrated that the CCR2(low/neg) cells are a distinct subpopulation and express lower levels of inflammatory cytokines and activation markers than their CCR2(high) counterparts. They exhibited impaired phagocytosis and greatly diminished chemotaxis in response to CCL2 and CCL7. In addition, these monocytes are refractory to SIV infection and suppress CD8(+) T cell proliferation in vitro. These cells express higher levels of STAT3 and NOS2, suggesting a phenotype similar to monocytic myeloid-derived cells, which suppress expansion of CD8(+) T cells in vivo. They may reflect an antiproliferative response against the extreme immune activation observed during HIV and SIV infections. In addition, they may suppress antiviral responses and thus, have a role in AIDS pathogenesis. Antiretroviral therapy in infected macaque and human subjects caused this population to decline, suggesting that this atypical phenotype is linked to viral replication. J. Leukoc. Biol. 91: 803-816; 2012.
Palavras-chave
macrophages, AIDS
URI
https://observatorio.fm.usp.br/handle/OPI/392
Referências
  1. Ancuta P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-403
  2. Barber SA, 2004, J NEUROVIROL, V10, P15, DOI 10.1080/13550280490268179
  3. Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423
  4. Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
  5. Bigley V, 2011, J EXP MED, V208, P227, DOI 10.1084/jem.20101459
  6. Bissel SJ, 2006, J NEUROIMMUNOL, V177, P85, DOI 10.1016/j.jneuroim.2006.04.017
  7. Burdo TH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000842
  8. Carter DL, 1999, CYTOMETRY, V37, P41, DOI 10.1002/(SICI)1097-0320(19990901)37:1<41::AID-CYTO5>3.0.CO;2-4
  9. Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039
  10. Clay CC, 2007, J VIROL, V81, P12040, DOI 10.1128/JVI.00133-07
  11. Clements JE, 2002, J INFECT DIS, V186, P905, DOI 10.1086/343768
  12. Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012
  13. Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
  14. Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09
  15. Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
  16. Filipazzi P., 2010, CANCER IMMUNOL IMMUN, V61, P255
  17. Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
  18. GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613
  19. Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
  20. Geissmann F, 2008, IMMUNOL CELL BIOL, V86, P398, DOI 10.1038/icb.2008.19
  21. Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
  22. Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682
  23. Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
  24. Grage-Griebenow E, 2001, EUR J IMMUNOL, V31, P48, DOI 10.1002/1521-4141(200101)31:1<48::AID-IMMU48>3.0.CO;2-5
  25. Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003
  26. Heinrich PC, 1998, BIOCHEM J, V334, P297
  27. Hieshima K, 1997, J BIOL CHEM, V272, P5846
  28. Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984
  29. Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399
  30. Kamp W, 2001, EUR J CLIN INVEST, V31, P984, DOI 10.1046/j.1365-2362.2001.00895.x
  31. KAZAZI F, 1989, J GEN VIROL, V70, P2661, DOI 10.1099/0022-1317-70-10-2661
  32. Kim WK, 2010, J LEUKOCYTE BIOL, V87, P557, DOI 10.1189/jlb.0209082
  33. Lafferty MK, 2010, BLOOD, V115, P1564, DOI 10.1182/blood-2009-06-226423
  34. Laforge M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002087
  35. Lewin SR, 1998, AIDS, V12, P719, DOI 10.1097/00002030-199807000-00008
  36. Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500
  37. Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820
  38. Margulies BJ, 2001, AIDS RES HUM RETROV, V17, P981, DOI 10.1089/088922201750290104
  39. Merino A, 2011, J IMMUNOL, V186, P1809, DOI 10.4049/jimmunol.1001866
  40. MIKOVITS JA, 1992, J CLIN INVEST, V90, P1486, DOI 10.1172/JCI116016
  41. Mizuno K, 2005, CLIN EXP IMMUNOL, V142, P461, DOI 10.1111/j.1365-2005.02932.x
  42. Nagaraj Srinivas, 2009, Cancer Res, V69, P7503, DOI 10.1158/0008-5472.CAN-09-2152
  43. Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529
  44. Otani I, 1998, AIDS RES HUM RETROV, V14, P1181, DOI 10.1089/aid.1998.14.1181
  45. Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1
  46. Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x
  47. Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969
  48. Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08
  49. Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191
  50. Sunderkotter C, 2004, J IMMUNOL, V172, P4410
  51. Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202
  52. Takeda S, 2010, DIGEST DIS SCI, V55, P1886, DOI 10.1007/s10620-009-0974-2
  53. Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
  54. Van Grol J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011733
  55. Vanham G, 1996, CLIN EXP IMMUNOL, V103, P30, DOI 10.1046/j.1365-2249.1996.907600.x
  56. Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011
  57. Velasco F, 2000, MATH GEOL, V32, P439, DOI 10.1023/A:1007573815959
  58. Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
  59. Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078
  60. Weber C, 2000, J LEUKOCYTE BIOL, V67, P699
  61. Witwer KW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008129
  62. Xu LL, 2000, EUR J IMMUNOL, V30, P227, DOI 10.1002/1521-4141(200001)30:1<227::AID-IMMU227>3.0.CO;2-X
  63. Yachie A, 2003, EXP BIOL MED, V228, P550
  64. Yona S, 2010, CURR OPIN HEMATOL, V17, P53, DOI 10.1097/MOH.0b013e3283324f80
  65. Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558
  66. Zink MC, 1999, J VIROL, V73, P10480
  67. Zink MC, 2001, J INFECT DIS, V184, P1015, DOI 10.1086/323478

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/60